Clinical Trial: NCT03546361
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Jonsson Comprehensive Cancer Center |
| Information Provided By: | Jonsson Comprehensive Cancer Center |
| Last Update Posted: | 2025-01-14 |
Study Overview
Brief Summary
This phase I trial studies the side effects and best dose of autologous dendritic cell-adenovirus CCL21 vaccine (CCL21-gene modified dendritic cell vaccine) combined with intravenous pembrolizumab, and to see how well they work in treating patients with stage IV non-small cell lung cancer. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving CCL21-gene modified dendritic cell vaccine with pembrolizumab may work better in treating patients with stage IV non-small cell lung cancer.
Official Title
Conditions
Intervention / Treatment
- Biological: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
- Biological: Pembrolizumab
Other Study ID Numbers
- 17-000174
- NCI-2018-01244
- HEMONC CIRM IST Lung
- K08CA245249
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Jonsson Comprehensive Cancer Center |
| Information Provided By: | Jonsson Comprehensive Cancer Center |
| Last Update Posted: | 2025-01-14 |
Study Overview
Brief Summary
This phase I trial studies the side effects and best dose of autologous dendritic cell-adenovirus CCL21 vaccine (CCL21-gene modified dendritic cell vaccine) combined with intravenous pembrolizumab, and to see how well they work in treating patients with stage IV non-small cell lung cancer. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving CCL21-gene modified dendritic cell vaccine with pembrolizumab may work better in treating patients with stage IV non-small cell lung cancer.
Official Title
Conditions
Intervention / Treatment
- Biological: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
- Biological: Pembrolizumab
Other Study ID Numbers
- 17-000174
- NCI-2018-01244
- HEMONC CIRM IST Lung
- K08CA245249